Bailard’s Esperion Therapeutics ESPR Stock Holding History

Bailard’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,000	Closed	-$212K	–	727
2021 Q2	$212K	Sell	10,000 -13,000	-57%	-$313K	0.01%	660
2021 Q1	$645K	Hold	23,000	–	–	0.02%	333
2020 Q4	$598K	Sell	23,000 -75,500	-77%	-$2.26M	0.03%	289
2020 Q3	$3.66M	Hold	98,500	–	–	0.19%	98
2020 Q2	$5.05M	Buy	98,500 +5,200	+6%	+$218K	0.28%	77
2020 Q1	$2.94M	Buy	93,300 +3,400	+4%	+$179K	0.21%	95
2019 Q4	$5.36M	Sell	89,900 -1,000	-1%	-$45K	0.3%	78
2019 Q3	$3.33M	Buy	90,900 +14,700	+19%	+$582K	0.2%	106
2019 Q2	$3.54M	Buy	76,200 +16,700	+28%	+$784K	0.22%	99
2019 Q1	$2.39M	Buy	59,500 +50,500	+561%	+$2.27M	0.15%	140
2018 Q4	$414K	Hold	9,000	–	–	0.03%	340
2018 Q3	$399K	Hold	9,000	–	–	0.02%	423
2018 Q2	$353K	Sell	9,000 -50,300	-85%	-$2.54M	0.02%	429
2018 Q1	$4.29M	Sell	59,300 -16,000	-21%	-$1.17M	0.27%	91
2017 Q4	$4.96M	Buy	75,300 +12,000	+19%	+$646K	0.31%	71
2017 Q3	$3.17M	Hold	63,300	–	–	0.25%	103
2017 Q2	$2.93M	Buy	63,300 +22,300	+54%	+$820K	0.24%	103
2017 Q1	$1.45M	Buy	+41,000	New	+$939K	0.12%	149
2016 Q1	–	Sell	-9,000	Closed	-$200K	–	283
2015 Q4	$200K	Buy	+9,000	New	+$227K	0.09%	191

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bailard's ESPR Position: Q3 2021 in Review

Bailard sold out of Esperion Therapeutics (ESPR) in Q3 2021, closing a stake of 10,000 shares — an estimated $212K sold.

Bailard first reported a position in ESPR in Q4 2015 and held it in 19 quarters. The position peaked at $5.36M in Q4 2019. 139 funds tracked by Wall St. Rank hold ESPR as of Q3 2021.

Bailard reported no remaining Esperion Therapeutics position as of Q3 2021 after selling out during the quarter.
Bailard sold 10,000 Esperion Therapeutics shares in Q3 2021, an estimated $212K.
Bailard first reported a position in Esperion Therapeutics in Q4 2015 and held it in 19 quarters.
Bailard's Esperion Therapeutics position peaked at $5.36M in Q4 2019.
139 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2021.

Based on Bailard's 13F filing for Q3 2021, filed 15 Nov 2021.